NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
Aachen, Germany (ots/PRNewswire) - Next.e.GO Mobile SE, the independent German manufacturer of innovative and sustainable urban electric vehicles, today announced the appointment of Martin C. Klein as the new Chief Executive Officer effective 01.12.2021. Martin Klein is an automotive industry veteran with over three decades of international experience, both on the OEM ...
Aachen, Germany (ots) - - Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry - Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies ...
Aachen, Germany (ots/PRNewswire) - Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective 1 January 2020. Since July 2019, Jan has already served as acting CSO, leading the strategic re-alignment of Grünenthal's R&D organisation. Jan brings over 15 years of experience in healthcare and the biopharmaceutical industry. He joined ...
Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...
Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...
Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...
Aachen, Germany / Redwood City (California), USA (ots) - Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self- administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, ...